Document Page: First | Prev | Next | All | Image | This Release | Search
File: aaavp_01.txtSUBJECT: BACKGROUND PAPER ON PARENTERAL DIAZEPAM IN SUPPORT OF DESERT PURPOSE: To outline the background of the requirements for parenteral diazepam in support of Desert Shield. BACKGROUND - Studies support the efficacy of diazepam given 1 minute after agent exposure in preventing or ameliorating nerve agent induced convulsions, preventing or minimizing brain injury, decreasing recovery time, and decreasing mortality. - The benefits of diazepam in nerve agent treatment were discussed with HQ Tac/SGPA on 13 Aug 90. - CENTAF/SG was briefed on this information and options for procurement of diazepam on 14 Aug 90. -- Option 1: Procure for field use FDA-approved, 10 mg pre-filled diazepam syringes from SPSC. --- 51K on hand. --- 5 K due in. -- Option 2: Ask US Army as Executive Agent for Medical Chemical Defense to procure diazepam autoinjectors (using the Combopen container) for field use. --- Army/SG holds IND for this R&D effort. --- FDA approval for use would be required, but is expected to be approved. --- Preliminary contacts with contractor indicate 30 K autoinjectors could be available within 4 weeks after issue of an urgent, sole-source contract. -- Option 3: Ask Army to procure 10 mg diazepam in flanged autoinjector planned for CANA (Convulsant Antidote: for Nerve Agent) program. ---- Longest lead time of 3 options. - CENTAF/SG decided on 14 Aug to implement Option 2. - Considering Option 1 as an interim "fix". -- Issue to CCP triage teams rather than individuals. --Each ATH has 1200 diazepam syringes available. - Stock fund $ are available to procure these items.
Document Page: First | Prev | Next | All | Image | This Release | Search